Pharming and SIPI collaboration includes Ruconest marketing in China
Dutch biotech company Pharming Group (NYSE Euronext: PHARM) and Shanghai Institute of Pharmaceutical Industry (SIPI), a Sinopharm Group company, have entered into a strategic collaboration for the development, manufacture and commercialization of new products based on the Pharming technology platform.
In addition, Pharming has granted SIPI an exclusive license to commercialize Ruconest (conestat alfa; recombinant human C1 esterase inhibitor) in China. Ruconest is approved in Europe for the treatment of acute angioedema attacks in patients with HAE.
SIPI will pay Pharming €1.26 million euros ($1.6 million) upfront for the collaboration and a total of 840,000 euros technology transfer related milestones associated with the implementation of the first technology transfer Ruconest.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze